A carregar...
Evaluating Response to High‐Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease
AIMS: To identify factors predicting improvement/stabilization on the Alzheimer's Disease Cooperative Study–Clinical Global Impression of Change (ADCS‐CGIC) and investigate whether early treatment responses can predict long‐term outcomes, during a trial of 13.3 mg/24 h versus 4.6 mg/24 h rivast...
Na minha lista:
| Publicado no: | CNS Neurosci Ther |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6495641/ https://ncbi.nlm.nih.gov/pubmed/25675992 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.12385 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|